UCB

(BRU-ENX)

Industry: Health Care seperator

Sector: Pharmaceuticals & Biotechnology

€ 59.97 <%= Resources.Global.txtDown %>

Updated 19/09/2017

Change %	-0.60%
Change	-0.36
Volume	235,866
High	€ 60.38
Low	€ 59.80
Open	€ 60.38
ISIN	BE0003739530
Prev close	€ 60.33
# of shares	183.37M
Market cap	10,996M EUR

Intraday

Market closed

Market is closed, opens at 08:00


Price development	Latest	1 week	1 month	3 months	6 months	1 year

	59.97	1.6%	4.6%	-3.5%	-16.3%	-18.4%

English
Regulatory news

	14 Sep	New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress

	25 Jul	UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis

	24 Mar	UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS

	19 Jan	Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

	08 Dec	Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

More news

Company | Investor | Advertising | Contact | Support

: IR services for listed companies

Facebook

Twitter

Copyright Euroinvestor A/S 2017 Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.

20 September 2017 03:09:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London

UCB

News about UCB

Company profile